Other

Duke University

The University of Texas System

University System of Maryland

Robert H Christenson

Robert M Califf

Kristina N Sigmon

E Magnus Ohman

Trevor D Thompson

L Kristin Newby

Robin T Vollmer

Show-Hong Duh

Stephen Seliger

Mary Ann O'Hanesian

Christopher Defilippi

James De Lemos

Magnus E Ohman

The present invention provides a method for predicting whether a human patient 65 years of age or older is at increased risk for developing heart failure, comprising obtaining the results of an assay that measures levels of NT-proBNP and/or cardiac troponin T in a specimen from the patient wherein an increased NT-proBNP and/or cardiac troponin T level compared to levels in a control indicate an increased risk for developing heart failure.

Methods for assessing differential risk for developing heart failure

This disclosure relates to the field of holders for the storage of hair care appliances and similar articles wherein the hair-care appliances are stored (held) for immediate use. A thermal barrier clip for use with flat irons is also disclosed for use with the holder so as to improve safety and increase the lifespan of the flat iron. A hair dryer hook is also disclosed which allows for storage of a hair dryer with a diffuser attached.

Hair appliance holder

This disclosure relates to the field of holders for the storage of hair care appliances and similar articles wherein the hair care appliances are stored (held) for immediate use. A thermal barrier clip for use with flat irons is also disclosed for use with the holder so as to improve safety and increase the lifespan of the flat iron. A hair dryer hook is also disclosed which allows for storage of a hair dryer with a diffuser attached.

Appliance holder

A method for predicting the clinical outcome for a patient after the patient has received therapy for an acute coronary syndrome such as myocardial infarction comprises: (a) optionally, but preferably, detecting a first variable comprising a serum creatine kinase-MB release curve area in the patient after initiation of said therapy; (b) detecting a second variable comprising a serum creatine kinase-MB release curve maxima in the patient after initiation of said therapy; then (c) optionally, but preferably, detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy (wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope); and (d) generating a prediction of clinical outcome for said patient from the variables collected above. The method is useful in conjunction with established therapies such as thrombolytic therapy, and is particularly useful as a surrogate end point in clinical trials of new potential therapies.

Methods for evaluating therapies and predicting clinical outcome related to coronary conditions

The present invention is a method of diagnosing the presence of a persistent occlusion in a myocardial infarct patient undergoing thrombolytic therapy. The method comprises detecting a series of five variables from the patient and then generating the probability of the presence of a persistent occlusion from those variables. The first variable comprises a serum creatine kinase MB (CK-MB) level from a patient at the onset of thrombolytic therapy. The second variable comprises a second CK-MB level in the patient at a predetermined time after the onset of thrombolytic therapy. The third variable comprises the presence or absence of chest pain a predetermined time after the onset of thrombolytic therapy. The fourth variable comprises the serum myoglobin level in the patient at a predetermined time after the onset of thrombolytic therapy. In a preferred embodiment of the present invention, the second, third and fourth variables are detected within 30 minutes of each other and within about 1 to about 3 hours after the initial variable is detected. In an alternate embodiment a fifth variable reflecting the time from onset of chest pain to the beginning of thrombolytic therapy is included in the regression model.

Method of assessing reperfusion after thrombolytic therapy

The present invention is a method of diagnosing the presence of a persistent occlusion in a myocardial infarct patient undergoing thrombolytic therapy. The method comprises detecting a series of three variables from the patient and then generating the probability of the presence of a persistent occlusion from those variables. The first variable comprises a serum creatine kinase MB (CK-MB) level from a patient at the onset of thrombolytic therapy. The second variable comprises a second CK-MB level in the patient at a predetermined time after the onset of thrombolytic therapy. The third variable comprises the presence or absence of chest pain a predetermined time after the onset of thrombolytic therapy. In a preferred embodiment of the present invention, the second and third variables are detected within 30 minutes of each other and within about 1 to about 3 hours after the initial variable is detected. In an alternate embodiment a fourth variable reflecting the time from onset of chest pain to the beginning of thrombolytic therapy is included in the regression model.

Growing community of inventors

Joppa, MD, United States of America

Robert H Christenson